Download PDFPDF
Extended report
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles

Share this article

Click the icon of the social media platform on which you would like to share this article.

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
(Your Name) has forwarded a page to you from Annals of the Rheumatic Diseases
(Your Name) thought you would like to see this page from the Annals of the Rheumatic Diseases web site.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.